Media
Webinars
Blog
Podcasts
2026
Beyond the Update - FDA's Revised Payor Communications Draft Guidance
This LinkedIn Live explored FDA’s revised draft guidance on manufacturer communications with payors, focusing on what has changed and what it means in practice for Regulatory, HEOR, and Market Access teams.
Host:
Chad Patel
Denise Sanchez
2024
Generative AI Use Cases: Part 1
May 6, 2024
Navigating State Prescription Drug Affordability Boards
March 25, 2024
Asking the right questions
March 13, 2024
Planting your IRA-ready Evidence Garden
February 22, 2024
2023
Weaving data visualization into presentations to elicit action
October 27, 2023
Pharmaceutical Value: In the Eyes of the [Payer] Beholder
September 20, 2023
Practice Makes Perfect: Preparing for IRA Negotiations
September 5, 2023
The Evolution of HCEI/PIE Opportunities- Are you up to Speed?
August 10, 2023
Reducing uncertainty in the EU HTA Regulation
April 14, 2023
2022
2020
2019
The Case for Early Payer Input into Medicine Development
October 19, 2019
Early Customer Engagement Wins the Race to Launch!
September 19, 2019
Internal Communication – Going Beyond Email and Shared Drives
August 19, 2019
2023
Redefining Care: How Specialty Pharmacy is Shaping the Future of Healthcare
On today's episode we will be discussing specialty pharmacy with Dr. Ruchik Patel (Associate Director, Management Consulting at AESARA) and Dr. Sonalie Patel (Program Director & Clinical Pharmacist at Northwestern Medicine).
Host:
Fadi Manuel
Guest:
Ruchik Patel
Sonalie Patel
Time stamps
00:00 – 02:37 Introduction
02:38 – 10:03 Overview of Specialty Pharmacy and Discussion on its Role
10:04 – 12:22 Introduction and Discussion on the Role of Specialty Pharmacist
12:41 – 15:28 Discussion on Current Challenges Faced by Specialty Pharmacists
15:46 – 17:31 Response to Challenges in Specialty Pharmacy
17:40 – 22:14 Real-World Experiences and Evidence Sharing
22:31 – 24:55 Significance of Evidence Generation in Specialty Pharmacy
25:20 – 27:09 Discussion on Additional Gaps and Opportunities in Specialty Pharmacy
Resources
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis
Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings
2022
The impact of the Inflation Reduction Act on Healthcare & Pharma
On today's episode we will be discussing the inflation reduction act with Dr. Chad Patel (Head of US Strategic Partnerships) and Dr. Phoenix Riley (Visiting Scientist).
Host:
Fadi Manuel
Guest:
Chad Patel
Phoenix Riley
Time stamps
01:34 – 04:11 Impact of the Inflation Reduction Act (IRA) on the healthcare industry
04:29 – 8:06 Medicare criteria for drug price negotiations
08:22 – 11:26 Impact of IRA on the pharmaceutical industry
11:37 – 13:33 Potential consequences of IRA on research initiatives
13:49 – 16:49 Drug price reforms in Europe
17:05 – 18:27 Pharma’s response to the IRA
18:41 – 20:37 Potential strategies in response to the IRA
Integrated Evidence Generation Planning I Gavin Outteridge
In our inaugural episode we are discussing integrated evidence generation planning (IEGP) in the pharmaceutical industry featuring our AESARA Europe Managing Director, Gavin Outteridge.
Host:
Fadi Manuel
Time stamps
1:13 – 7:16 Defining IEGP and its Benefits
7:24 – 11:00 Shortcomings in the current evidence generation approach
11:13 – 14:45 Impact on patient outcomes
15:04 – 20:29 Challenges to the IEGP process
20:43 – 23:35 Use of technology to improve process & closing comments
